Growth hormone response to growth hormone-releasing hormone stimulation in obsessive-compulsive disorder

Psychiatry Research

Volumn 81, Issue 3, 1998, Pages 293-299

  Brambilla, Francesca ^a   Bellodi, Laura ^a   Perna, Giampaolo ^a   Arancio, Cinzia ^a   Bertani, Angelo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Endocrine factors; Obsessive compulsive disorder; Somatomedin C; Somatotropic axis

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GROWTH HORMONE RELEASE; HUMAN; MALE; NEGATIVE FEEDBACK; NEUROTRANSMISSION; OBSESSION; PATHOGENESIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; FEEDBACK; FEMALE; GROWTH HORMONE-RELEASING HORMONE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; REFERENCE VALUES;

EID: 0032517866     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(98)00124-3     Document Type: Article

References (42)

1. Abelson J.L., Glitz D., Cameron O.G., Lee M.A., Bronzo M., Curtis G.C. Blunted growth hormone response to clonidine in patients with generalized anxiety dsorder. Archives of General Psychiatry. 48:1991;157-162.
2. Altemus M., Pigott T., L'Heureux F., Davis C.L., Rubinow D.R., Murphy D.L., Gold P.N. CSF somatostatin in obsessive-compulsive disorder. American Journal of Psychiatry. 150:1993;460-464.
3. American Psychiatric Association, 1987. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders, 3rd revised ed. American Psychiatric Press, Washington, DC.
4. Benkelfat C., Mefford I.N., Masters C.F., Nordahl T.E., King A.C., Cohen R.M., Murphy D.L. Plasma catecholamines and their metabolites in obsessive-compulsive disorder. Psychiatry Research. 37:1991;321-331.
5. Blanchard, M., Charrier, L., Kann, G.N., Garandel, V., Fraysse, A., Barenton, B., 1989. Influence d'un traitement chronique au GRF (1-21) ou au clenbuterol chez la brebis en fin de gestation sur I'activité de l'axe somatotrope fetale et maternel. (Abstract) Annales d'Endocrinologie 50, 256.
6. Brambilla F., Perna G., Bellodi L., Arancio C., Bertani A., Perini G., Carraro C., Gava F. Noradrenergic receptor sensitivity in obsessive-compulsive disorders: growth hormone response to clonidine stimulation. Psychiatry Research. 69:1997;155-162.
7. Brambilla F., Bellodi L., Perna G., Arancio C., Bertani A., Perini G., Carraro C., Gava F. Noradrenergic receptor sensitivity in obsessive-compulsive disorders: II. Cortisol response to acute clonidine administration. Psychiatry Research. 69:1997;163-168.
8. Brambilla F., Bellodi L., Perna G., Arancio C., Bertani A. Dopamine function in obsessive-compulsive disorder: growth hormone response to apomorphine stimulation. Biological Psychiatry. 42:1997;889-897.
9. Erikson, E., 1985. Brain α-2-adrenoceptor function and growth hormone release. In: Experimental Psychoneuroendocrinology. Medi Press, Goteborg.
10. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischman R.L., Hill C.L., Heninger G.R., Charney D.S. The Yale-Brown Obsessive-Compulsive Scale. I. Development, use and reliability. Archives of General Psychiatry. 46:1989;1006-1011.
11. Harel Z., Tannenbaum G.S. Dietary protein restriction impairs both spontaneous and growth hormone-releasing factor-stimulated growth hormone release in the rat. Endocrinology. 133:1993;1035-1043.
12. Ho K.Y., Evans W.R., Blizzard R.M., Veldhuis J.D., Merriam G.R., Samoljlik E., Furlanetto R., Rogol A.D., Kaiser D.L., Thorner M.O. Effects of sex and age on the h profile of growth hormone secretion in man: importance of endogenous estradiol concentations. Journal of Clinical Endocrinology and Metabolism. 64:1987;51-58.
13. Hollander E., DeCaria C.M., Nitescu A., Cooper T.B., Stover B., Gully R., Klein D.F., Liebowitz M.R. Noradrenergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to clonidine and comparison to healthy control subjects. Psychiatry Research. 37:1991;161-179.
14. Hollander E., Liebowitz M.R., DeCaria C.M. Conceptual and methodological issues in studies of obsessive-compulsive and Tourette's disorders. Psychiatric Development. 4:1989;276-296.
15. Hollander E., Stein D.J., Saoud J.B., DeCaria C.M., Cooper T.B., Trungold S., Stanley M., Liebowitz M.R. Effects of fenfluramine on plasma HVA in OCD. Psychiatry Research. 42:1992;185-188.
16. Khanna S., Reddy P.L., Subhash M.N., Rao B.S.S.S., Channabasavanna S.M. Neuroendocrine profile of obsessive-compulsive disorder. Neuroendocrinology Letters. 10:1988;250.
17. Lang I., Schernthaner G., Pietschmann P., Kurz R., Stephenson J.M., Templ H. Effect of sex and age on growth hormone in healthy individuals. Journal of Clinical Endocrinology and Metabolism. 65:1987;535-540.
18. Lee M.A., Cameron O.G., Gurguis G.N.M., Glitz D., Smith C.B., Hariharan M., Abelson L.L., Curtis G. Alpha-2-adrenoceptor status in obsessive-compulsive disorder. Biological Psychiatry. 27:1990;1083-1093.
19. Lesch K.P., Erb A. Growth hormone (GH) responses to GH-releasing hormone in depression: correlation with GH release following clonidine. Psychiatry Research. 25:1988;301-310.
20. Lesch K.P., Laux G., Pfuller H., Erb A., Beckmann H. Growth hormone (GH) response to GH-releasing hormone in depression. Journal of Clinical Endocrinology and Metabolism. 65:1987;1278-1281.
21. Lucey J.V., Barry S., Webb M.G., Dinan T.G. The desipramine-induced growth hormone response and the dexamethasone suppression test in obsessive-compulsive disorder. Acta Psychiatrica Scandinavica. 86:1992;367-370.
22. Lucey J.V., Butcher G., Clare A.W., Dinan T.G. Elevated growth hormone responses to pyridostigmine in obsessive-compulsive disorder: evidence of cholinergic supersensitivity. American Journal of Psychiatry. 150:1993;961-962.
23. Martin L.G., Clark J.W., Conner T.B. Growth hormone secretion enhanced by androgens. Journal of Clinical Endocrinology and Metabolism. 28:1968;425-429.
24. Masuda A., Shibasaki T., Nakahara M., Imaki T., Kiyosawa Y., Jibiki K., Demura H., Shizume K., Ling N. The effect of glucose on growth hormone (GH) releasing hormone-mediated GH secretion in man. Journal of Clinical Endocrinology and Metabolism. 60:1985;523-526.
25. Marazziti D., Hollander E., Lensi P., Ravagli S., Cassano L.B. Peripheral markers of serotonin and dopamine function in obsessive-compulsive disorder. Psychiatry Research. 42:1992;41-52.
26. Muller E.E. Neural control of somatotropic function. Physiological Review. 3:1987;962-1053.
27. Pavia C., Valls C., Gallart M. Priming with GHRH (1-29)-NH-2 as a useful tool in the origin diagnosis of growth hormone (GH) deficiency. Acta Medica Auxologica. 25:1993;133-138.
28. Pieters G.F.F.M., Smals A.G.H., Kloppenborg P.W.C. Defective suppression of growth hormone after oral glucose loading in adolescence. Journal of Clinical Endocrinology and Metabolism. 51:1980;265-270.
29. Rasmussen S.A., Goodman W.K., Woods S.W., Heninger G.R., Charney D.S. Effects of yohimbine in obsessive-compulsive disorder. Psychopharmacology. 93:1987;308-313.
30. Reichard B., Schrader M., Mojto J., Mehltretter G., Muller O.A., Schopohl L. The decrease in growth hormone (GH) response after repeated stimulation with GH-releasing hormone is partly caused by an elevation of somatostatin tonus. Journal of Clinical Endocrinology and Metabolism. 81:1996;1994-1998.
31. Robins, L., Helzer, L.E., Cottler, L., Goldring, E., 1989. NIMH Diagnostic Interview Schedule: Version III-R (DIS-III-R). Washington University Medical School, St. Louis, MO.
32. Roy B.F., Benkelfat C., Hill L.L., Pierce P.F., Dauphin M.M., Kelly T.M., Sunderland T., Weinberger D.R., Breslin N. Serum antibody for somatostatin-14 and prodynorphin 209-240 in patients with obsessive-compulsive disorder, schizophrenia, Alzheimer's disease, multiple sclerosis and advanced HIV infection. Biological Psychiatry. 35:1994;335-344.
33. Schulman D.I., Sweetland M., Duckett G., Root A.W. Effect of estrogen on the growth hormone (GH) secretory response to GH-releasing factor in the castrate adult female rat in vivo. Endocrinology. 120:1987;1047-1051.
34. Siever L.J., Insel T.R., Jimerson D.C., Lake R.C., Uhde T.W., Aloi J., Murphy D.L. Growth hormone response to clonidine in obsessive-compulsive patients. British Journal of Psychiatry. 142:1983;184-187.
35. Skare S.S., Dysken M.W., Billington C.J. A review of the GHRH stimulation test in psychiatry. Biological Psychiatry. 36:1994;249-265.
36. Smals D.I., Sweetland M., Duckett G., Root A.W. Effect of estrogen on the growth hormone (GH) secretory response to GH-releasing factor in the castrate adult female rat in vivo. Endocrinoogy. 120:1986;1047-1051.
37. Swedo S.E., Leonard H.L., Kruesi M.J.P., Rette D.C., Listvak S.J., Berrettini W., Stipetic M., Hamburger S., Gold P.W., Potter W.Z., Rapoport J.L. Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. Archives of General Psychiatry. 49:1992;29-36.
38. én et al., 1980
39. Thorén P., Åsberg M., Bertilsson L., Mellström B., Sjöqvist R., Träskman L. Chlomipramine treatment of obsessive-compulsive disorders. II Biochemical aspects. Archives of General Psychiatry. 37:1980;1289-1294.
40. Trestman R.L., Coccaro E.F., Lawrence T., Knott P., Gabriel S.M., Siever L.J. The stability of plasma growth hormone and X1HPG responses to repeated clonidine challenge in normal males. Psychoneuroendocrinology. 19:1994;13-20.
41. Weissberger A.J., Ho K.Y., Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-h growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in post-menopausal women. Journal of Clinical Endocrinology and Metabolism. 72:1991;374-381.
42. Williams T., Berelowitz M., Joffe S.N., Thorner M.O., Rivier J., Vale W., Frohman L.A. Impaired growth hormone responses to growth hormone-releasing factor in obesity. New England Journal of Medicine. 211:1984;1403-1407.